Clinical trial
A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous…
NCT00297921 · Millennium Pharmaceuticals, Inc., Industry · Withdrawn
Key facts
| NCT number | NCT00297921 |
|---|---|
| Title | A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | tandutinib |
| Enrollment | 0 |
| First posted | Mar 1, 2006 |
| Last update posted | Nov 6, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: